drugset / Trial / NCT01789736
A Study Assessing PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components for 28 Days
RandomizedParallel-groupQuadruple-blindTreatment
Summary
In the double-masked, randomized, multi-center, active-controlled parallel study, patients will be randomized to receive either a fixed dose combination of AR-12286 and travoprost, AR-12286, or travoprost. The hypothesis is that there is no difference between each treatment arm.
Timeline
- Start
- 2013-02
- Primary completion
- 2013-06
- Completion
- 2013-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PG286 | Unknown | 0.5 % | Other |
| Comparator | Travoprost | Other / unclassified | 0.004 % | Other |
| Subject | VEROSUDIL | Small molecule | 0.5 % | Other |